Using CRISPR technology to eliminate HIV from the body
CRISPR for Cure
This study is exploring new ways to use CRISPR gene editing to help people with HIV by boosting their immune systems and potentially getting rid of the virus completely, so that patients might have better treatment options and a chance for a lasting cure.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Temple Univ of the Commonwealth NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11077289 on NIH RePORTER |
What this research studies
This research aims to develop innovative therapies using CRISPR gene editing to target and eliminate HIV from the body. It focuses on enhancing the immune system's ability to control the virus and aims to eradicate latent infections that can reactivate when treatment is stopped. The project involves a collaborative team of scientists and community stakeholders, utilizing advanced techniques like next-generation sequencing to understand the HIV reservoir and improve immune responses. Patients may benefit from new treatment options that could lead to a functional cure for HIV.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who are currently on antiretroviral therapy and are interested in potential new treatment options.
Not a fit: Patients who are not living with HIV or those who are not on antiretroviral therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a functional cure for HIV, allowing patients to live without the need for continuous antiretroviral therapy.
How similar studies have performed: Other research has shown promise in using CRISPR technology for gene editing, indicating potential for success in this novel approach to HIV treatment.
Where this research is happening
Philadelphia, United States
- Temple Univ of the Commonwealth — Philadelphia, United States (Active)
Researchers
- Principal investigator: Khalili, Kamel — Temple Univ of the Commonwealth
- Study coordinator: Khalili, Kamel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.